Aurinia Pharmaceuticals

$6.38
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.14 (2.17%) Today
-$0.21 (-3.19%) As of 7:41 PM EDT after-hours

Why Robinhood?

You can buy or sell AUPH and other stocks, options, ETFs, and crypto commission-free!

About AUPH

Aurinia Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of a therapeutic drug to treat autoimmune diseases particularly lupus nephritis. The company was founded by Robert Foster, Richard Glickman and Michael Martin on June 16, 1993 and is headquartered in Victoria, Canada.

Employees
39
Headquarters
Victoria, British Columbia
Founded
1993
Market Cap
605.16M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
655.62K
High Today
$6.62
Low Today
$6.43
Open Price
$6.44
Volume
514.64K
52 Week High
$7.85
52 Week Low
$5.06

Collections

AUPH Earnings

-$0.21
-$0.15
-$0.10
-$0.04
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Estimated
Actual
Expected Nov 7, After Hours

Popular Stocks

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.